Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

Daan W. Huntjens, Jacob A. Dijkstra, Lisanne N. Verwiel, Mirjam Slijkhuis, Paul Elbers, Matthijs R. A. Welkers, Agnes I. Veldkamp, Marianne A. Kuijvenhoven, David C. de Leeuw, H. Abdullah-Koolmees, Maria T. Kuipers, Imke H. BartelinkPharmaceutics 2023 · DOI

TL;DR

Severely immunocompromised patients are at high risk for serious HSV and CMV infections, but current antiviral treatments are challenging due to narrow therapeutic windows and significant variability in how patients process these drugs. This review proposes optimizing treatment through early resistance detection, therapeutic drug monitoring (TDM), and the strategic use of newer antivirals and drug combinations to improve patient outcomes.

What Problem Does This Paper Address?

Herpes simplex virus (HSV) and cytomegalovirus (CMV) are common viruses that can cause severe, even life-threatening, infections in individuals with weakened immune systems, particularly those who have undergone allogeneic hematopoietic stem cell transplantation (allo-HCT). Treating these infections is complex because antiviral drugs have a narrow therapeutic window (meaning the difference between an effective dose and a toxic dose is small) and their effectiveness can vary greatly between individuals due to factors like kidney function and other medications. This variability makes it difficult to determine the optimal dose, leading to potential underdosing (ineffectiveness and resistance development) or overdosing (toxicity). The paper addresses the need for better strategies to manage HSV and CMV infections in this vulnerable population by reviewing current knowledge and proposing improvements.

Methods

This paper is a scoping review. This means the authors systematically searched and synthesized existing literature on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antiviral drugs used for HSV and CMV treatment in immunocompromised patients. They reviewed current treatment guidelines and proposed interventions based on this gathered knowledge. The review focuses on understanding how the body processes these drugs (PK) and how the drugs affect the virus and the patient (PD) to inform better treatment strategies.

Datasets

Not discussed in the paper. This is a review article, not an empirical study with primary data collection.

Key Insights and Ideas

  • PK/PD Variability is a Major Hurdle: The significant inter-patient variability in how antiviral drugs are absorbed, distributed, metabolized, and excreted (PK) directly impacts their effectiveness and toxicity (PD), making standard dosing insufficient for many immunocompromised patients.
  • TDM is Crucial for Nucleoside Analogs: For drugs like acyclovir and ganciclovir, which are nucleoside analogs, Therapeutic Drug Monitoring (TDM) is highlighted as a key strategy. By measuring drug concentrations in the blood, clinicians can adjust doses to ensure they stay within the effective and safe range, especially in patients with altered PK due to comorbidities.
  • Newer Drugs Offer Hope: The review points to newer antiviral agents (e.g., pritelivir, amenamevir, letermovir, maribavir, brincidofovir) that have different mechanisms of action or improved PK/PD profiles, offering alternative or complementary options, particularly for resistant infections.
  • Resistance is a Growing Concern: Long-term antiviral use and suboptimal dosing contribute to the development of drug resistance, a significant challenge in immunocompromised patients. Early detection of resistance through genotypic and phenotypic testing is crucial.
  • Combination Therapy and Alternation: The paper suggests that combining synergistic antiviral drugs or alternating between drugs with different toxicity profiles could be beneficial strategies to overcome resistance and manage toxicity.

Key Results

The paper doesn't present new experimental results but synthesizes existing knowledge to propose improved treatment strategies. Key "results" are the proposed interventions:

  • Early Detection of Drug Resistance: Implementing routine or triggered drug resistance testing.
  • Optimization of Dose via TDM: Utilizing TDM for nucleoside analogs to achieve target concentrations, especially when response is suboptimal or toxicity is a concern.
  • Introduction of New Antivirals: Strategically incorporating newer agents like pritelivir, amenamevir, letermovir, maribavir, and brincidofovir earlier in treatment regimens, particularly for resistant or refractory cases.
  • Alternating or Combining Antivirals: Employing strategies that combine drugs with different mechanisms or toxicity profiles to improve efficacy and reduce adverse events.

The review also highlights the limitations of current treatments, such as the nephrotoxicity of foscarnet and cidofovir, and the myelotoxicity of ganciclovir, underscoring the need for these optimized approaches.

Limitations and Future Work

The authors acknowledge that the limited number of patients in clinical trials for newer antivirals, the limited revenue for pharmaceutical companies developing drugs for niche populations, and the need for high dosages to achieve therapeutic concentrations at all relevant viral sites are significant limitations.

They strongly advocate for prospective, randomized controlled trials to rigorously evaluate the proposed interventions, including the benefit of TDM, combination therapies, and the earlier use of novel agents. Further research is also needed to better understand the relationship between plasma drug exposure and intracellular concentrations, as well as the impact of the patient's immune response on treatment outcomes. Quantifying the patient's immune status (e.g., using interferon-γ release assays) and assessing the interplay between immunosuppressive drugs and antiviral efficacy are also suggested areas for future investigation.

Summary updated

Abstract

Herpes simplex virus (HSV) and cytomegalovirus (CMV) are DNA viruses that are common among humans. Severely immunocompromised patients are at increased risk of developing HSV or CMV disease due to a weakened immune system. Antiviral therapy can be challenging because these drugs have a narrow therapeutic window and show significant pharmacokinetic variability. Above that, immunocompromised patients have various comorbidities like impaired renal function and are exposed to polypharmacy. This scoping review discusses the current pharmacokinetic (PK) and pharmacodynamic (PD) knowledge of antiviral drugs for HSV and CMV treatment in immunocompromised patients. HSV and CMV treatment guidelines are discussed, and multiple treatment interventions are proposed: early detection of drug resistance; optimization of dose to target concentration by therapeutic drug monitoring (TDM) of nucleoside analogs; the introduction of new antiviral drugs; alternation between compounds with different toxicity profiles; and combinations of synergistic antiviral drugs. This research will also serve as guidance for future research, which should focus on prospective evaluation of the benefit of each of these interventions in randomized controlled trials.
BibTeX
@inproceedings{huntjens2023optimizing,
  author = {Daan W. Huntjens and Jacob A. Dijkstra and Lisanne N. Verwiel and Mirjam Slijkhuis and Paul Elbers and Matthijs R. A. Welkers and Agnes I. Veldkamp and Marianne A. Kuijvenhoven and David C. de Leeuw and H. Abdullah-Koolmees and Maria T. Kuipers and Imke H. Bartelink},
  title = {{Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients}},
  booktitle = {Pharmaceutics},
  year = {2023},
  doi = {10.3390/pharmaceutics15010163},
}
Figure